Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

BACKGROUND: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Piedra, C, Alcaraz, A, Bellmunt, J, Meseguer, C, Gómez-Caamano, A, Ribal, M J, Vázquez, F, Anido, U, Samper, P, Esteban, E, Álvarez-Ossorio, J L, Lara, P C, San José, L A, Contreras, J A, del Alba, A G, González-Gragera, B, Tabernero, A J, González-Enguita, C, Fernández, J M, García-Escudero, A, Gómez-Veiga, F, Méndez, M J, Segarra, J, Virizuela, J A, Carles, J, Lassa, A, Calderero, V, Constela, M, Delgado, D, Mañas, A, Murias, A, Reynes, G, Rodriguez, B, Rubio, G, Sánchez, E, Unda, M, Solsona, E, Martínez-Javaloyas, J M, Comet-Batlle, J, Quicios, C, Martín-Fernández, M, Mahillo-Fernández, I, Morote, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694249/
https://www.ncbi.nlm.nih.gov/pubmed/23722472
http://dx.doi.org/10.1038/bjc.2013.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694249/
https://www.ncbi.nlm.nih.gov/pubmed/23722472
http://dx.doi.org/10.1038/bjc.2013.270

Ejemplares similares